NCT04410094View on ClinicalTrials.gov

A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 14, 2020

Primary Completion Date

December 30, 2020

Study Completion Date

February 2, 2021

Conditions
Healthy
Interventions
DRUG

Lazertinib

Lazertinib tablets will be administered orally.

DRUG

Itraconazole

Itraconazole capsules will be administered orally.

DRUG

Rifampin

Rifampin capsules will be administered orally.

Trial Locations (1)

85283

Celerion, Tempe

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04410094 - A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult Participants | Biotech Hunter | Biotech Hunter